Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population.
OBJECTIVE
To identify the relative incidence and profile of adverse drug reaction (ADR) to various topical ocular hypotensives in a hospital setting.


METHODS
All the patients presenting in outpatients clinic and accident and emergency with an ADR to topical hypotensive agent from August 2000 to January 2001 were included in the study. Details regarding the type date of commencing the treatment, the date of developing ADR, time to resolution of the ADR were noted.


RESULTS
Over the period of 6 months, 66 patients presented with 73 ADRs. Brimonidine was the most frequent offending agent. In total, 23 (34.8%) presented with ADR after being commenced on treatment for more than 12 months. In all, 16 (24%) patients had IOP > 21 on presentation, eight (12%) patients underwent filtration surgery following the development of ADR.


CONCLUSIONS
Adverse drug reaction to ocular hypotensive agents is not uncommon and can have a major impact on glaucoma management. Delayed presentation and association with raised intraocular pressure presentation emphasise the need for effective patient education to encourage prompt reporting of ADR.
Bhatt
R
R
Wolverhampton & Midland Counties Eye Infirmary, Wolverhampton WV3 9QR, UK.
Whittaker
K W
KW
Appaswamy
S
S
Desai
A
A
Fitt
A
A
Sandramouli
S
S
D000316:Adrenergic alpha-Agonists / Q000009:adverse effects; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000009:adverse effects*; D000068438:Brimonidine Tartrate; D005260:Female; D018463:Filtering Surgery; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000009:adverse effects; D010044:Outpatient Clinics, Hospital; D010342:Patient Acceptance of Health Care; D011446:Prospective Studies; D011810:Quinoxalines / Q000009:adverse effects; D013997:Time Factors
D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D000068438:Brimonidine Tartrate